Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15526554 | 0.90 | SCN9A (0.42) | SCN9ASTAT3ROCK2ROCK1DGAT1 | |
| SCHEMBL14889895 | 0.87 | SCN9A (0.49) | SCN9ACETP | |
| SCHEMBL15526486 | 0.82 | ADH5 (0.48) | SCN9AROCK2ROCK1 | |
| SCHEMBL1132317 | 0.79 | CNR1 (0.44) | STAT3CNR1CNR2CA12CA1 | |
| SCHEMBL1424795 | 0.79 | TDP1 (0.41) | STAT3CNR1CNR2CA12CA1 | |
| SCHEMBL16198591 | 0.78 | USP30 (0.37) | DGAT1CETPHTR7 | |
| SCHEMBL16649978 | 0.77 | CETP (0.43) | SCN9ACETPSLC2A1 | |
| SCHEMBL14426491 | 0.75 | STAT3 (0.48) | STAT3CA12CA1CA2CA9 | |
| SCHEMBL16659027 | 0.74 | SCN9A (0.55) | SCN9ASLC2A1 | |
| SCHEMBL4828805 | 0.72 | SLC6A2 (0.51) | STAT3CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9717714-B2 | Spirocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2844252-B1 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9353101-B2 | Cyclic amine substituted heterocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353101-B2 | Cyclic amine substituted heterocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150342931-A1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150111866-A1 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111866-A1 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111866-A1 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS | CETP, APOB, MTTP | SCN9A 2592/4885STAT3 4854/4885ROCK2 4141/4885 |
| US-20150342931-A1 | SPIROCYCLIC CETP INHIBITORS | CETP, MTTP, LCAT | SCN9A 2081/4885STAT3 4630/4885ROCK2 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.